Loading...

MIST MILESTONE PHARMACEUTICALS INC US FDA Inspections 8-K Filing

MLST

MST

MILESTONE PHARMACEUTICALS INC

(MIST)

2025 8-K

Show Summary

Show Summary

Pre-Market Approval

Financial Statements

Shareholder Meeting

Share Sale Agreement

Financial Results

Corporate Presentation

Q3 Financial Results

Board Appointment

Financial Results Announcement

Cooperation Agreement with ...

Financial Results Announcement

Financial Results Announcement

Underwriting Agreement for ...

FDA Refusal to File Letter

Financial Results Announcement

Other Special Situation

NDA Submission for Etripami...

Financial Results and Update

Annual Meeting of Shareholders

Financial Results Announcement

Creation of Financial Oblig...

Financial Results Announcement

Purchase and Sale Agreement...

Management Changes

Regulation FD Disclosure

Corporate Presentation

External Links:

On June 16, 2025, Milestone Pharmaceuticals Inc. submitted a response to the FDA regarding their drug CARDAMYST (etripamil) nasal spray intended for treating a heart condition. This filing reflects an ongoing effort to gain approval for the medication.

AI Assistant

MILESTONE PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.